KCT0007344尚未招募未知
A single-arm, phase II study of axitinib and chemotherapy in patients with recurred or metastatic salivary gland cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 20(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1. Histologically confirmed salivary gland cancer
- •(adenoid cystic carcinoma, mucoepidermoid carcinoma, mammary analog secretory carcinoma, acinic cell carcinoma, adenocarcinoma NOS, salivary ductal carcinoma carcinoma))
- •2. Locally advanced or metastatic local disease with evidence of disease progression when comparing imaging findings (CT, MRI, X-ray) taken within the last 9 months with imaging findings just before registration. (Progress should be documented in accordance with RECIST 1.1 criteria.)
- •3. Those with a disease that cannot be expected to be cured by surgery, radiation, or combination therapy for therapeutic purposes, and those who are above the 1st line
- •4. Presence of at least one measurable target lesion based on RECIST 1.1
- •5. Age 19 or older
- •6. ECOG performance status 0, 1
- •7. Subjects previously treated with chemotherapy or topical therapy are permitted if their toxicity resolved to grade 1 or lower at trial enrollment and the last treatment was performed at least 4 weeks prior to baseline evaluation.
- •8. Proper organ function
- •Absolute neutrophil count (ANC) = 1500/µL
- •Platelets =100,000/µL
- •Hemoglobin (Hb) = 9.0 g/dL
- •Serum creatinine = 1.5 times the upper limit of normal (ULN)
- •Serum bilirubin = 1.5 times the upper limit of normal (ULN)
- •AST, ALT = 3.0 times upper limit of normal (ULN) (with or without liver metastasis)
- •9. Subjects who are willing and able to comply with the trial protocol during the trial period
- •10. Subjects who sign a written informed consent prior to participation in the study and understand that they have the right to withdraw their consent from participation in the study at any time without penalty
排除标准
- •1. Subjects without measurable lesions
- •2. Subjects who underwent chemotherapy, radiation therapy, or surgery within 4 weeks prior to study enrollment, except palliative radiation therapy for non-target lesions (administered within 2 weeks prior to study enrollment)
- •3. Subjects with intestinal obstruction or urge obstruction, recent active upper gastrointestinal bleeding
- •4. Pregnant or lactating women
- •5. Subjects of childbearing potential who did not have a pregnancy test or have a positive result at baseline. (Post-menopausal women with amenorrhoea longer than 12 months are considered fertile.)
- •6. Men or women of childbearing age who are unwilling to use contraceptive methods during the trial
- •7. Subjects with a history of other malignant diseases within the past 5 years, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ
- •8. Subjects with a history of uncontrolled seizures, central nervous system disorders, or psychiatric disorders judged to be clinically significant by the investigator, which could interfere with the understanding of written informed consent or affect compliance with the study drug
- •9. Subjects who have experienced clinically significant heart disease (e.g., congestive heart failure, symptomatic coronary artery disease, cardiac arrhythmias, etc.) or myocardial infarction within the past 12 months
- •10. Subjects who have undergone organ transplant requiring immunosuppressive therapy
- •11. Subjects with severe hypersensitivity to the active ingredient or excipient of Axitinib
- •12. Hypertension that is not controlled by medication (>160/100mmHg)
- •13. Those with a history of deep vein thrombosis or pulmonary embolism within the past 6 months
- •14. Those with a history of severe pulmonary hemorrhage or hemoptysis within the past 6 months
- •15. Those with a history of uncontrolled coagulation disorder
- •16. Those who have a history of treatment with angiogenesis inhibitors before
- •17. Those who must take strong CYP3A4 derivatives (carbamazepine, dexamethasone, felbamate, omeprazole, phenobarbital, amobarbital, phenytoin, primidone, rifabutin, rifampin, nevirapine, St John’s wort)
- •18. Symptomatic brain and spinal cord metastases
- •19. Uncontrolled pleural fluid, pericardial fluid, or ascites
研究者
相似试验
进行中（未招募）
1 期
A clinicopathological phase II study of axitinib in patients with advanced angiosarcoma and other soft tissue sarcomas - Axi-STS Trial, version 1Soft tissue sarcomaEUCTR2008-006007-23-GBSheffield Teaching Hospitals NHS Foundation Trust152
已完成
2 期
A Phase II study of axitinib in patients with metastatic renal cell cancer unsuitable for nephrectomyCancerISRCTN72679844Institute of Cancer Research (UK)65
进行中（未招募）
1 期
Phase II study of axitinib intensification plus nivolumab compared to nivolumab alone after induction with nivolumab plus ipilimumab in mRCC patients without previous complete response (AxIn study)metastatic renal cell carcinoma (mRCC)MedDRA version: 21.1Level: PTClassification code: 10050513Term: Metastatic renal cell carcinoma Class: 100000004864CTIS2024-511397-70-00Consorzio Oncotech118
进行中（未招募）
1 期
Phase 2 trial of axitinib and TRC105 versus axitinib alone in patients with advanced or metastatic renal cell carcinomaADVANCED OR METASTATIC RENAL CELL CARCINOMAMedDRA version: 20.0 Level: PT Classification code 10050513 Term: Metastatic renal cell carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-003436-13-CZTRACON Pharmaceuticals, Inc.150
进行中（未招募）
1 期
RANDOMIZED, DOUBLE-BLIND PHASE 2 STUDY OF AXITINIB (AG-013736) WITH OR WITHOUT DOSE TITRATION IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMAMetastatic RCCMedDRA version: 9.1Level: LLTClassification code 10050513Term: Metastatic renal cell carcinomaEUCTR2008-007786-23-CZPfizer Inc 235 East 42nd Street, New York, NY10017200